<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104232">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948661</url>
  </required_header>
  <id_info>
    <org_study_id>GAL 02</org_study_id>
    <nct_id>NCT01948661</nct_id>
  </id_info>
  <brief_title>Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma</brief_title>
  <acronym>MIRACOL</acronym>
  <official_title>Randomized Window of Opportunity Trial of Anthocyanin Extract and Phospholipid Curcumin in Subjects With Colorectal Adenoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ente Ospedaliero Ospedali Galliera</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Umberto Veronesi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indena spa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ente Ospedaliero Ospedali Galliera</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colonic adenomatous polyps are pre cancer lesions and are used as intermediate markers for
      testing agents with potential cancer prevention.

      Meriva© is a bioavailable form of curcumin, a polyphenolic compound obtained from turmeric
      (Curcuma longa L.) endowed with anti-inflammatory, antioxidant and antitumor effects. In
      vivo data indicate that curcumin formulated with phosphatidylcholine furnishes higher blood
      levels of parent agent than natural curcumin.

      Mirtoselect©, an anthocyanin mixture from bilberry containing isolated cyanidin-3-glucoside
      (C3G), the most abundant anthocyanin in diet, prevents intestinal adenoma formation in the
      Apc(Min) mouse model.

      The investigators hypothesize that the combination of both agents will decrease the
      expression of proteins involved in colon tumorigenesis relative to placebo.

      The change of biomarker expression between pre-treatment biopsy and post-treatment
      endoscopic resection in the target adenoma and the normal rectal mucosa will be the response
      measures.

      The primary response measure is the change of immunohistochemical (IHC) expression of
      β-catenin in adenomatous tissue and normal rectal mucosa. Secondary response measures are
      the changes of IHC Nuclear Factor-Kβ (NFKβ), cell proliferation by Ki-67 Labeling Index and
      apoptosis by P53 in adenomatous and adjacent normal mucosa.

      The study design is a phase II, randomized, double blind, placebo controlled,  window of
      opportunity trial of the combination of Mirtoselect 1 gr/day+Meriva 1 gr/day or placebo.
      Subjects with histological confirmation of colorectal adenomatous polyps &gt;1 cm not suitable
      to immediate complete removal will be enrolled in a 4-week intervention trial before
      endoscopic polypectomy.

      The demonstration of a biological activity of the two agent combination may provide the
      rationale for a phase III trial aimed at reducing the risk of colon cancer in high risk
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change of immunohistochemical expression of beta catenin in normal and adenomatous colonic tissue</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of IHC Nuclear Factor-Kβ (NFKβ), Ki-67 Labeling Index and P53 in normal and adenomatous mucosa.</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Adenoma</condition>
  <condition>Risk Reduction</condition>
  <arm_group>
    <arm_group_label>Anthocyanins+Phospholipidic Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirtoselect ® 500 mg tablet, 1000 mg (two oral tablets) per day and Meriva ®, 500 mg tablet, 1000 mg (two oral tablets) per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placeboA + placeboB</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placeboA + placeboB per day for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mirtoselect® + Meriva®</intervention_name>
    <arm_group_label>Anthocyanins+Phospholipidic Curcumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subjects with colorectal adenomatous polyps greater than 1 cm in maximum diameter not
             suitable to immediate complete removal;

          -  Normal renal and hepatic function;

          -  WHO Performance status=0;

        Exclusion Criteria:

          -  Presence of hyperplastic polyps and/or flat adenomas;

          -  Subjects with pre-existing colorectal cancer;

          -  Presence of carcinomatous tissue in adenoma;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea DeCensi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology Ente Ospedaliero Ospedali Galliera</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea DeCensi, MD</last_name>
    <phone>+39 010 563</phone>
    <phone_ext>4501</phone_ext>
    <email>andrea.decensi@galliera.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Oncology Ente Ospedaliero Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea DeCensi, MD</last_name>
      <phone>+39010 563</phone>
      <phone_ext>4501</phone_ext>
      <email>andrea.decensi@galliera.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>January 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ente Ospedaliero Ospedali Galliera</investigator_affiliation>
    <investigator_full_name>Andrea DeCensi</investigator_full_name>
    <investigator_title>Medical Oncology Director</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
